Skip to main content
. 2024 Nov 6;17:4875–4885. doi: 10.2147/IDR.S480520

Table 3.

Factors Related to 30-Day Mortality Rates

Factor Mortality (%) Relative Risk (RR), p
Charlson’s Comorbidity Indexa
 ≥ 6 points
 < 6 points		 31.1
12.6		 2.63, %95 CI: 1.22–4.96, p=0.010
PSIb
 Class I–IV
 Class V		 13.8
32.4		 2.43, %95 CI: 1.18–4.65, p=0.014
CURB-65 scorec
 0–1 point
 2-3-4 points		 7.0
28.1		 3.77, %95 CI: 1.58–9.48, p= 0.004
Age in years
 < 65
 65–80
 > 80		 9.3
24.5
28.5		 0.37, %95 CI: 0.15–0.85,
p= 0.013
(< 65 vs ≥ 65)
Initial response to treatment
 Yes
 No		 7.0
51.4		 6.48%95 CI: 2.63–15.94, p<0.001
Respiratory Rates (ResR)
 ≤ 20 vs > 20
 < 22 vs ≥ 22
 < 30 vs ≥ 30		 8.7 vs 25.6
8.6 vs 25.9
14.4 vs 32.2		 2.92, %95 CI: 1.16–7.32, p=0.02
3.01, %95 CI: 1.26–7.55, p=0.01
2.23, %95 CI: 1.11–4.46, p=0.02
Pulmonary Infiltration
 Lobar
 Atypical/Multilobar		 12.9
24.6		 p=0.087
Sputum Culture
 No Growth
 PsA+ Polymicrobial		 15.7
35.2		 2.07, %95 CI:1.04–4.82, p=0.049d
Empirical Antibiotherapy
 Beta-lactam monotherapy
 Combined antibiotic regimene 		24.4
20.8		 p>0.05

Notes: aCCI; Charlson comorbidity index, bPSI; Pneumonia severity index, cCURB-65 score; Confusion, urea, respiratory rate, blood pressure, dNo growth detection vs growth detected, emacrolide or quinolone plus beta-lactam.